In 2025 ICON’s Creative and Digital Services and Global Medical Communications teams were recognised for delivering impactful medical communications for clients. https://ow.ly/ncCE50XSQ0P
Download Global and China biotech survey reports
Two new survey reports of 260+ Global and China-based biotech leaders are ready to download
Get your copy nowFrom bottlenecks to breakthroughs
Human-centred strategies for faster study starts
Read the whitepaperOptimising vaccine follow-up through early planning
A proactive approach to RWD and tokenisation integration
Read the whitepaperDeveloping AI in software as a medical device (SaMD)
Model and data selection best practices
Read the whitepaper
Featured solutions
EngageAI
Our voice of the customer feedback platform has been enhanced using AI; transforming how we listen, respond, and act on your feedback.
Blended solutions
Bespoke, seamless solutions to meet unique sponsor challenges.
Outcome Measures
A multi-faceted approach to identifying, selecting, and implementing evidence-based measures that matter to patients.
Biotech
ICON provides full service outsourcing and flexible support for biotech specific needs such as due diligence and asset valuation.
Cardiac Safety Solutions
End-to-end cardiac safety solutions, including ECG, event monitoring, BPM, long-term Holter monitoring, ECHO and MUGA studies.
Early Clinical and Bioanalytical Solutions
Innovative early clinical solutions that will advance your drug development strategy.
Site & Patient Solutions
Transforming recruitment through patient-centric trials and real-world, real-time data.
Market Access
Expertise in mission-critical pricing, market access, and reimbursement.
Specialty Laboratory Solutions
Supporting precision medicine programs across all phases of drug diagnostic co-development.
Webinars
When patients lead: Breaking barriers in ultra-rare disease drug development
3 March 2026. Register today.
Beyond the bench: The advantages of GMP over USP compounding in early phase development
Watch the webinar.
Boosting clinical trial success in Alzheimer’s, Parkinson’s and other neurodegenerative diseases
Watch the webinar.